Kardigan (KARD) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.45B and a free-cash-flow yield of -16.9%. Nama's AI scorecard rates it Sell, 4.0 out of 10.
AI scorecard
Sell · 4.0/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-42.5%
How far the last close sits under the highest price of the past five years.
Market cap
$1.45B
Trailing P/E
—
Price / book
2.2
Price / sales
—
FCF yield
-16.9%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
KARD earnings
Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$1.04).
Beat the EPS estimate in 0 of 1 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 11, 2026
-$2.89
-$0.64
-351.6%
$0
KARD analyst price target
Median target $42.50 from 8 analysts, ranging $25.00 – $50.00.
Nama's AI scorecard currently rates Kardigan Sell (4.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does KARD report earnings?
Kardigan's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$1.04.
What is the KARD price target?
The median analyst price target from 8 analysts is $42.50, with a range of $25.00 – $50.00.
Is KARD Shariah compliant?
Nama's AAOIFI-style screen reads Kardigan as Not Shariah Compliant. At least one of the three ratios or the industry test failed.